Chondroitin sulfate - IBSA

Drug Profile

Chondroitin sulfate - IBSA

Alternative Names: Chondroitin 4-sulfate - IBSA; Chondroitin 4-sulfate sodium - IBSA; Chondroitin 6-sulfate - IBSA; Chondroitin 6-sulfate sodium - IBSA; Chondroitin sulfate A - IBSA; Chondroitin sulfate A sodium - IBSA; Chondroitin sulfate sodium - IBSA; Chondroitin sulphate - IBSA; Chondrosulf; Condrosulf (IBSA); Condrosulf (Salus Braumapharm)

Latest Information Update: 28 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IBSA
  • Developer IBSA; Laboratoires Genevrier; Sanova Pharma; SPA
  • Class Anti-inflammatories; Antirheumatics; Glycosaminoglycans
  • Mechanism of Action Collagen stimulants; Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 13 Jun 2016 Efficacy data from the phase III CONCEPT trial released by IBSA
  • 14 Apr 2014 Phase-III clinical trials in Osteoarthritis in Belgium (PO) (EudraCT2013-001619-62)
  • 14 Apr 2014 Phase-III clinical trials in Osteoarthritis in Poland (PO) (EudraCT2013-001619-62)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top